Literature DB >> 21312284

Long-term clinical outcome in meige syndrome treated with internal pallidum deep brain stimulation.

René Reese1, Doreen Gruber, Thomas Schoenecker, Hansjörg Bäzner, Christian Blahak, H Holger Capelle, Daniela Falk, Jan Herzog, Marcus O Pinsker, Gerd H Schneider, Christoph Schrader, Günther Deuschl, Hubertus M Mehdorn, Andreas Kupsch, Jens Volkmann, Joachim K Krauss.   

Abstract

Deep brain stimulation of the globus pallidus internus (GPi DBS) is effective in the treatment of primary segmental and generalized dystonia. Although limb, neck, or truncal dystonia are markedly improved, orofacial dystonia is ameliorated to a lesser extent. Nevertheless, several case reports and small cohort studies have described favorable short-term results of GPi DBS in patients with severe Meige syndrome. Here, we extend this preliminary experience by reporting long-term outcome in a multicenter case series, following 12 patients (6 women, 6 men) with Meige syndrome for up to 78 months after bilateral GPi DBS. We retrospectively assessed dystonia severity based on preoperative and postoperative video documentation. Mean age of patients at surgery was 64.5 ± 4.4 years, and mean disease duration 8.3 ± 4.4 years. Dystonia severity as assessed by the Burke-Fahn-Marsden Dystonia Rating Scale showed a mean improvement of 45% at short-term follow-up (4.4 ± 1.5 months; P < 0.001) and of 53% at long-term follow-up (38.8 ± 21.7 months; P < 0.001). Subscores for eyes were improved by 38% (P = 0.004) and 47% (P < 0.001), for mouth by 50% (P < 0.001) and 56% (P < 0.001), and for speech/swallowing by 44% (P = 0.058) and 64% (P = 0.004). Mean improvements were 25% (P = 0.006) and 38% (P < 0.001) on the Blepharospasm Movement Scale and 44% (P < 0.001) and 49% (P < 0.001) on the Abnormal Involuntary Movement Scale. This series, which is the first to demonstrate a long-term follow-up in a large number of patients, shows that GPi DBS is a safe and highly effective therapy for Meige syndrome. The benefit is preserved for up to 6 years.
Copyright © 2011 Movement Disorder Society.

Entities:  

Mesh:

Year:  2011        PMID: 21312284     DOI: 10.1002/mds.23549

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  36 in total

Review 1.  Dystonia rating scales: critique and recommendations.

Authors:  Alberto Albanese; Francesca Del Sorbo; Cynthia Comella; H A Jinnah; Jonathan W Mink; Bart Post; Marie Vidailhet; Jens Volkmann; Thomas T Warner; Albert F G Leentjens; Pablo Martinez-Martin; Glenn T Stebbins; Christopher G Goetz; Anette Schrag
Journal:  Mov Disord       Date:  2013-06-15       Impact factor: 10.338

Review 2.  Treatment of dystonia.

Authors:  Mary Ann Thenganatt; Joseph Jankovic
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 3.  [Deep brain stimulation for hyperkinetic movement disorders].

Authors:  M M Reich; J Volkmann
Journal:  Nervenarzt       Date:  2014-02       Impact factor: 1.214

Review 4.  Diagnosis and treatment of dystonia.

Authors:  H A Jinnah; Stewart A Factor
Journal:  Neurol Clin       Date:  2015-02       Impact factor: 3.806

5.  Successful Treatment of Blepharospasm by Pallidal Neurostimulation.

Authors:  Ana Filipa Santos; Andreia Veiga; Luís Augusto; Rui Vaz; Maria José Rosas; Jens Volkmann
Journal:  Mov Disord Clin Pract       Date:  2016-01-05

Review 6.  Arching deep brain stimulation in dystonia types.

Authors:  Han-Joon Kim; Beomseok Jeon
Journal:  J Neural Transm (Vienna)       Date:  2021-03-19       Impact factor: 3.575

Review 7.  Blepharospasm 40 years later.

Authors:  Giovanni Defazio; Mark Hallett; Hyder A Jinnah; Antonella Conte; Alfredo Berardelli
Journal:  Mov Disord       Date:  2017-02-10       Impact factor: 10.338

Review 8.  [Deep brain stimulation for movement disorders].

Authors:  F Steigerwald; J Volkmann
Journal:  Nervenarzt       Date:  2012-08       Impact factor: 1.214

Review 9.  Medical and Surgical Treatments for Dystonia.

Authors:  H A Jinnah
Journal:  Neurol Clin       Date:  2020-03-02       Impact factor: 3.806

Review 10.  Treatment of Dystonia: Medications, Neurotoxins, Neuromodulation, and Rehabilitation.

Authors:  Ian O Bledsoe; Aaron C Viser; Marta San Luciano
Journal:  Neurotherapeutics       Date:  2020-10-23       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.